Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,issuanceOfStock,repurchaseOfStock,totalCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,dividendDate,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ELDN,102837000.0,14306600,5590000,,-9000000,,-8499000,3415000,0,-9005000,-9005000,,,,,,-501000,0,9005000,0,5000,,-8499000,-8499000,32386000.0,272749000.0,7811000.0,183871000.0,191682000.0,14000.0,26000.0,-88892000.0,3605000.0,48648000.0,315000.0,108579000.0,4206000.0,92000.0,110241000.0,197000.0,1514000.0,2220000.0,-450000.0,-206000.0,-5616000.0,-5166000.0,46000.0,-450000.0,1273000.0,,,,106035000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,8.302,1630506516,-0.017999649,8.27,8.302,8.1941,3636,0,"Eledon Pharmaceuticals, Inc.",REGULAR,us_market,-0.21634194,8.1941 - 8.302,8.32,8.15,8.3,40,8,finmb_62494905,NasdaqCM,"Eledon Pharmaceuticals, Inc.",USD,73398,85383,2.3969998,0.40592715,5.905 - 27.32,-19.018,-0.69612,1601856000,5.905,27.32,1620936000,1636973940,1637323200,0.22773322,9.894196,-1.5921955,-0.16092218,-2.53,-3.281423,6.7620554,1.5399446,118773392,15,America/New_York,EDT,-14400000,False,False,1.97,,,27.32,5.91,6.76,9.89,73.4k,85.38k,14.31M,,8.86M,9.27%,65.96%,165.32k,2.44,1.16%,1.16%,471.92k,,,,,,0.00%,"Oct 04, 2020",,1:18,"Oct 04, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-11.51%,-23.65%,,,,,-18.91M,-23.13M,,,108.58M,7.59,97k,0.05,26.21,,-18.18M,-5.29M,Value,92612,Healthcare,10,"Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",Irvine,949 238 8090,CA,1609372800,United States,http://eledon.com,86400,19900 MacArthur Boulevard,Biotechnology,Suite 550
t-1,ELDN,109562000.0,14306600,2976000,,-6308000,,-5904000,482000,0,-3458000,-3458000,,,,,,-404000,0,3458000,0,-2850000,,-5904000,-5904000,32386000.0,270974000.0,6589000.0,190596000.0,197185000.0,15000.0,38000.0,-80393000.0,4106000.0,48648000.0,383000.0,114195000.0,2483000.0,138000.0,115630000.0,110000.0,1366000.0,-4050000.0,9164000.0,-779000.0,-269000.0,-9433000.0,45000.0,-450000.0,1255000.0,9189000.0,-25000.0,,113147000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,8.302,1630506516,-0.017999649,8.27,8.302,8.1941,3636,0,"Eledon Pharmaceuticals, Inc.",REGULAR,us_market,-0.21634194,8.1941 - 8.302,8.32,8.15,8.3,40,8,finmb_62494905,NasdaqCM,"Eledon Pharmaceuticals, Inc.",USD,73398,85383,2.3969998,0.40592715,5.905 - 27.32,-19.018,-0.69612,1601856000,5.905,27.32,1620936000,1636973940,1637323200,0.22773322,9.894196,-1.5921955,-0.16092218,-2.53,-3.281423,6.7620554,1.5399446,118773392,15,America/New_York,EDT,-14400000,False,False,1.97,,,27.32,5.91,6.76,9.89,73.4k,85.38k,14.31M,,8.86M,9.27%,65.96%,165.32k,2.44,1.16%,1.16%,471.92k,,,,,,0.00%,"Oct 04, 2020",,1:18,"Oct 04, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-11.51%,-23.65%,,,,,-18.91M,-23.13M,,,108.58M,7.59,97k,0.05,26.21,,-18.18M,-5.29M,Value,92612,Healthcare,10,"Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",Irvine,949 238 8090,CA,1609372800,United States,http://eledon.com,86400,19900 MacArthur Boulevard,Biotechnology,Suite 550
t-2,ELDN,-55346000.0,14306600,565000,,-6144000,,-6144000,3781000,0,-4346000,-4346000,,,,,,0,0,4346000,0,-1798000,,-6144000,-6144000,32386000.0,95994000.0,6130000.0,21506000.0,192585000.0,1000.0,17000.0,-74489000.0,,44466000.0,449000.0,114464000.0,6130000.0,183000.0,115101000.0,214000.0,758000.0,4244000.0,95226000.0,415000.0,105700000.0,-561000.0,46000.0,-450000.0,878000.0,9189000.0,-25000.0,11035000.0,108971000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,8.302,1630506516,-0.017999649,8.27,8.302,8.1941,3636,0,"Eledon Pharmaceuticals, Inc.",REGULAR,us_market,-0.21634194,8.1941 - 8.302,8.32,8.15,8.3,40,8,finmb_62494905,NasdaqCM,"Eledon Pharmaceuticals, Inc.",USD,73398,85383,2.3969998,0.40592715,5.905 - 27.32,-19.018,-0.69612,1601856000,5.905,27.32,1620936000,1636973940,1637323200,0.22773322,9.894196,-1.5921955,-0.16092218,-2.53,-3.281423,6.7620554,1.5399446,118773392,15,America/New_York,EDT,-14400000,False,False,1.97,,,27.32,5.91,6.76,9.89,73.4k,85.38k,14.31M,,8.86M,9.27%,65.96%,165.32k,2.44,1.16%,1.16%,471.92k,,,,,,0.00%,"Oct 04, 2020",,1:18,"Oct 04, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-11.51%,-23.65%,,,,,-18.91M,-23.13M,,,108.58M,7.59,97k,0.05,26.21,,-18.18M,-5.29M,Value,92612,Healthcare,10,"Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",Irvine,949 238 8090,CA,1609372800,United States,http://eledon.com,86400,19900 MacArthur Boulevard,Biotechnology,Suite 550
t-3,ELDN,9356000.0,14306600,785000,,-2586000,,-2586000,1316000,0,-2101000,-2101000,,,,,,0,0,2101000,0,-485000,,-2586000,-2586000,,77682000.0,1145000.0,9356000.0,10501000.0,19000.0,83000.0,-68345000.0,,,511000.0,8764000.0,1097000.0,229000.0,9761000.0,162000.0,150000.0,-785000.0,95226000.0,107000.0,-3021000.0,-3021000.0,46000.0,-450000.0,197000.0,9189000.0,-25000.0,11035000.0,8664000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,8.302,1630506516,-0.017999649,8.27,8.302,8.1941,3636,0,"Eledon Pharmaceuticals, Inc.",REGULAR,us_market,-0.21634194,8.1941 - 8.302,8.32,8.15,8.3,40,8,finmb_62494905,NasdaqCM,"Eledon Pharmaceuticals, Inc.",USD,73398,85383,2.3969998,0.40592715,5.905 - 27.32,-19.018,-0.69612,1601856000,5.905,27.32,1620936000,1636973940,1637323200,0.22773322,9.894196,-1.5921955,-0.16092218,-2.53,-3.281423,6.7620554,1.5399446,118773392,15,America/New_York,EDT,-14400000,False,False,1.97,,,27.32,5.91,6.76,9.89,73.4k,85.38k,14.31M,,8.86M,9.27%,65.96%,165.32k,2.44,1.16%,1.16%,471.92k,,,,,,0.00%,"Oct 04, 2020",,1:18,"Oct 04, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-11.51%,-23.65%,,,,,-18.91M,-23.13M,,,108.58M,7.59,97k,0.05,26.21,,-18.18M,-5.29M,Value,92612,Healthcare,10,"Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",Irvine,949 238 8090,CA,1609372800,United States,http://eledon.com,86400,19900 MacArthur Boulevard,Biotechnology,Suite 550
